Duality Biotherapeutics (HKSE:09606) Research & Development: HK$ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09606 Duality Biotherapeutics Inc HKSE:09606
9 GF Score
Price HK$178.20
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Research & Development?

Duality Biotherapeutics HKSE:09606 -1.22% 9 Research & Development is HK$ Mil as of Jun. 2026. GuruFocus rates HKSE:09606 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Duality Biotherapeutics's Research & Development for the six months ended in Jun. 2026 was HK$686.5 Mil. Duality Biotherapeutics does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Jun. 2026.

Duality Biotherapeutics  (HKSE:09606) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Duality Biotherapeutics Research & Development Related Terms

Duality Biotherapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Research & Development Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
395.06 615.65 902.47 901.29

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Research & Development 372.09 530.57 686.45
HKSE:09606
9GF Score
Duality Biotherapeutics Inc HKSE:09606
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$ Mil mean?
Duality Biotherapeutics (HKSE:09606) has a Research & Development of HK$ Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' Research & Development too high?
Duality Biotherapeutics' current Research & Development is HK$ Mil. Overall, Duality Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Research & Development compare to VRTX and REGN?
Duality Biotherapeutics' Research & Development of HK$ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Research & Development is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (HKSE:09606) has a current Research & Development of HK$ Mil. The current Research & Development is HK$ Mil. Duality Biotherapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Duality Biotherapeutics (HKSE:09606), the current Research & Development is HK$ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 4ZB:Germany
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
9GF Score

Get the complete analysis for HKSE:09606

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$178.20
Price